Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201542 - Dawar Richa

  • Investigator:
    Richa Dawar
    RCname Email

    Coordinator:

    IRB: 20201542

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester

    Title:

    A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer

    Eligibility Criteria - NCT03831932 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190887 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Violeta Milic
    RCphone 305-243-5181

    IRB: 20190887

    SDG: Gynecologic Cancer
    Disease Site(s):

    Lung,Ovary

    Sponsor: MER

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

    Eligibility Criteria - NCT03319628 *This information has been extracted from " www.clinicaltrials.gov"

  • LUNGMAP - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:
    RCemailImg Michelle Munevar
    RCphone +1 (305) 2437530

    IRB: 20200142

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: SWOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

    Eligibility Criteria - NCT03851445 *This information has been extracted from " www.clinicaltrials.gov"

  • MAVERICK - Libardi Dal Pra, Alan

  • Investigator:
    Alan Libardi Dal Pra
    RCname Email

    Coordinator:

    IRB: 20200727

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: SWOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) - S1827

    Eligibility Criteria - NCT04155034 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210031 - Libardi Dal Pra Alan

  • Investigator:
    Alan Libardi Dal Pra
    RCname Email

    Coordinator:

    IRB: 20210031

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)

    Eligibility Criteria - NCT04158141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210032 - Libardi Dal Pra Alan

  • Investigator:
    Alan Libardi Dal Pra
    RCname Email

    Coordinator:

    IRB: 20210032

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

    Eligibility Criteria - NCT04402788 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210035 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20210035

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: BEIGENE

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

    Eligibility Criteria - NCT04047862 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-01937 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20210174

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: MERCK KGAA

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2 Study)

    Eligibility Criteria - NCT03940703 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210785 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20210785

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: Jounce Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2First-in-Human(FIH)Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy andin Combination with a Programmed Cell Death Receptor-1 (PD-1)Inhibitor, in Adult Subjects with AdvancedRefractorySolid TumorMalignancies

    Eligibility Criteria - NCT04669899 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210977 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20210977

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: Nuvalent

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 inPatients with Advanced NSCLC and Other Solid Tumors (ARROS-1)

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210871 - Rodriguez Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:

    IRB: 20210871

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester

    Title:

    A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology

    Eligibility Criteria - NCT04216316 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00714 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190673

    SDG: Other
    Disease Site(s):

    Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20200938

    SDG: Other
    Disease Site(s):

    Breast,Colon,Lung,Melanoma, skin,Ovary

    Sponsor: Atreca Inc

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies

    Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"